Cargando…

c-Met Targeting Enhances the Effect of Irradiation and Chemical Agents against Malignant Colon Cells Harboring a KRAS Mutation

Although EGFR-targeted therapy has been beneficial to colorectal cancer patients, several studies have showed this clinical benefit was restricted to patients with wild-type KRAS exon 2 colorectal cancer. Therefore, it is crucial to explore efficient treatment strategies in patients with KRAS mutati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yingbo, Wang, Jinxi, Gao, Xing, Han, Weihua, Zheng, Yongxiang, Xu, Huan, Zhang, Chuanling, He, Qiuchen, Zhang, Lihe, Li, Zhongxin, Zhou, Demin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245100/ https://www.ncbi.nlm.nih.gov/pubmed/25427200 http://dx.doi.org/10.1371/journal.pone.0113186

Ejemplares similares

Data on interaction between adeno-associated virus and U87 cell via cRGD chemical modification
por: Zhang, Chuanling, et al.
Publicado: (2016)

Broadening the versatility of lentiviral vectors as a tool in nucleic acid research via genetic code expansion
por: Zheng, Yongxiang, et al.
Publicado: (2015)

Elevated Expression of AKR1C3 Increases Resistance of Cancer Cells to Ionizing Radiation via Modulation of Oxidative Stress
por: Xiong, Wei, et al.
Publicado: (2014)

Strand antagonism in RNAi: an explanation of differences in potency between intracellularly expressed siRNA and shRNA
por: Jin, Xin, et al.
Publicado: (2012)

Strand antagonism in RNAi: an explanation of differences in potency between intracellularly expressed siRNA and shRNA
por: Jin, Xin, et al.
Publicado: (2020)

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification
por: Sun, Dantong, et al.
Publicado: (2022)

Site-Specific PEGylated Adeno-Associated Viruses with Increased Serum Stability and Reduced Immunogenicity
por: Yao, Tianzhuo, et al.
Publicado: (2017)

Pancreatic cyst fluid harboring a KRAS mutation
por: Al-Turkmani, M. Rabie, et al.
Publicado: (2019)

Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations
por: Hu, Yan, et al.
Publicado: (2020)

Gastrointestinal malignancies harbor actionable MET exon 14 deletions
por: Lee, Jeeyun, et al.
Publicado: (2015)

The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
por: Albers, Joachim, et al.
Publicado: (2023)

Synthesis and structure-activity relationship studies of water-soluble β-cyclodextrin-glycyrrhetinic acid conjugates as potential anti-influenza virus agents
por: Liang, Shuobin, et al.
Publicado: (2019)

3D-printed scaffold harboring copper ions combined with near-infrared irradiation for local therapy of cancer
por: Wei, Hao, et al.
Publicado: (2023)

A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS
por: Zhang, Xiang-Hua, et al.
Publicado: (2013)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
por: Liu, Li, et al.
Publicado: (2021)

Generation of a caged lentiviral vector through an unnatural amino acid for photo-switchable transduction
por: Wang, Yan, et al.
Publicado: (2019)

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
por: Arbour, Kathryn C., et al.
Publicado: (2021)

Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration
por: Drilon, Alexander, et al.
Publicado: (2020)

Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib
por: Li, Jian, et al.
Publicado: (2022)

KRAS mutations are negatively correlated with immunity in colon cancer
por: Fu, Xiaorui, et al.
Publicado: (2020)

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary
por: Palma, Norma A., et al.
Publicado: (2014)

Fatty acid synthase cooperates with protrudin to facilitate membrane outgrowth of cellular protrusions
por: Zhang, Chuanling, et al.
Publicado: (2017)

Tuning the photoluminescence property of carbon dots by ultraviolet light irradiation
por: Li, Xiaoyu, et al.
Publicado: (2019)

Case Report: Effectiveness of Targeted Treatment in a Patient With Pancreatic Cancer Harboring PALB2 Germline Mutation and KRAS Somatic Mutation
por: Wu, Wei, et al.
Publicado: (2022)

Enhancing the Radiation Response in KRAS Mutant Colorectal Cancers Using the c-Met Inhibitor Crizotinib()()()
por: Cuneo, Kyle C., et al.
Publicado: (2018)

KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block
por: Garcia-Robledo, Juan Esteban, et al.
Publicado: (2022)

MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis
por: Lu, Daniel, et al.
Publicado: (2022)

Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification
por: Wang, Xiaomeng, et al.
Publicado: (2021)

Complete response to sotorasib as neoadjuvant treatment in patient with locally advanced primary pulmonary sarcoma harboring KRAS mutation: a case report
por: Li, Ce, et al.
Publicado: (2022)

KRAS: A Druggable Target in Colon Cancer Patients
por: Negri, Francesca, et al.
Publicado: (2022)

Construction of a reference material panel for detecting KRAS/NRAS/EGFR/BRAF/MET mutations in plasma ctDNA
por: Xu, Jun, et al.
Publicado: (2021)

PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas
por: Klein, Christian H., et al.
Publicado: (2018)

Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations
por: Ogasawara, Aiko, et al.
Publicado: (2020)

Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation
por: Nitta, Naohiro, et al.
Publicado: (2023)

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
por: Korpanty, Grzegorz J., et al.
Publicado: (2014)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
por: Colombino, Maria, et al.
Publicado: (2019)

Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations
por: Lu, Shun, et al.
Publicado: (2022)

KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
por: Lin, Yu-Lin, et al.
Publicado: (2012)

Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report
por: Liu, Junfang, et al.
Publicado: (2022)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mnhag1qt42rrra2evs852ssnl6